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Abstract: The oncogenic phosphatidylinositol 3-kinase-AKT-mammlian target of rapamycin pathway (PI3K-AKTmTOR) pathway is known to be activated in uterine smooth muscle tumors, and Stathmin 1 (STMN1) expression
has been identified as a marker of PI3K-AKT-mTOR pathway activation. We hypothesized that STMN1 may have
some diagnostic utility and explored how well STMN1 expression correlated with histologic classifications of uterine
smooth muscle tumors into benign and malignant groupings. 84 smooth muscle tumors were assessed for STMN1
expression by immunohistochemistry. These included spindle cell leiomyosarcoma (n = 32), conventional spindle
cell leiomyomas (n = 30), atypical (symplastic) leiomyoma (n = 5), cellular leiomyoma (n = 7), smooth muscle tumor
of uncertain malignant potential (n = 4), mitotically active leiomyomas (n = 2), benign metastasizing leiomyoma (n =
3), and cotyledonoid dissecting leiomyoma (n = 1). All spindle cell leiomyosarcomas were positive (32/32 positive;
100%) as compared with conventional leiomyomata (11/30; 37%) (P < 0.0001). The average immunohistochemical
score (0-12+, reflective of intensity and extent) for leiomyosarcomas was 8.7 (± 1.43) whereas the conventional
leiomyomata average score was 1.6 (± 1.07) (P < 0.0001). This difference in scores was reflected in the patterns
of expression: leiomyosarcomas were predominantly strongly and diffusely positive whereas leiomyomata were
predominantly weakly, albeit diffusely positive when expression was present. The sensitivity of STMN1 expression
for leiomyosarcomas was 100%. However, the specificity was found to be only 55% (CI = 43-68%). The negative
and positive predictive values for leiomyosarcomas were 100% and 52% respectively. The odds ratio (OR) for any
STMN1 expression in predicting a spindle cell leiomyosarcoma diagnosis from this dataset was highly significant (OR
= 144, P = 0.0006). Thirteen non-smooth muscle tumors that involved the uterus all showed at least focal STMN1
immunoreactivity. In summary, STMN1 is a highly sensitive marker for leiomyosarcoma but is suboptimally specific
for diagnostic purposes. The 100% negative predictive value for leiomyosarcoma may offer some diagnostic utility in
a small sample, since the absence of STMN1 immunoreactivity in a putative leiomyosarcoma is a strong argument
against this diagnostic possibility.
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Introduction
Uterine leiomyosarcomas are rare, representing approximately 1% of uterine malignancies,
40% of all uterine sarcomas, and with an annual incidence of approximately 0.64 per 100,000
women [1-5]. Although these are rare tumors,

leiomyosarcomas are clinically aggressive, with
5-year survival rates of between 25-75% [3,
6-11]. In general, pathologic classifications of
smooth muscle tumors show a strong correlation with patient outcomes. However, it has long
been recognized that the diagnosis of some
smooth muscle tumors can be problematic,
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This pathway is known to be highly activated in
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[27-32]. Accordingly, we hypothesized that STMN1 has some diagnostic utility in classifying
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malignant potential and explored how well
STMN1 expression correlated with histologic
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summary, STMN1 is a highly sensitive marker
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Figure 2. Leiomyosarcoma: diffuse expression of
STMN1 in leiomyosarcoma. Necrotic areas show decreased expression.

mas, one Ewing sarcoma, one perivascular epithelioid tumor, one pleomorphic rhabdomyosarcomas, one embryonal rhabdomyosarcomas,
one alveolar soft part sarcoma, one dedifferentiated liposarcoma, and one osteosarcoma.
Immunohistochemistry
Immunohistochemical analyses were performed on 1 unstained slide from each case.
Slides were placed on the Leica Bond Max
immunohistochemical stainer. All steps besides
dehydration, clearing and coverslipping are performed on the Bond Max. Slides are deparaffinized. Heat induced antigen retrieval was performed on the Bond Max using their Epitope
Retrieval 2 solution for 20 minutes. The sections were incubated with a polyclonal antibody
to STMN1 (Cell Signaling, Danvers, MA; Catalog
#3352) diluted 1:50 for one hour. The Bond
Refine Polymer detection system was used for
visualization. Slides were then dehydrated,
cleared and coverslipped.

Figure 3. Leiomyoma.

Specificity, Positive Predictive Value, Negative
Predictive Value for any STMN1 immunoreactivity in predicting the leiomyosarcoma diagnosis
were determined using three thresholds for
positivity (≥ 1+, ≥ 4+, and ≥ 6+) using the vassarstats program (http://www.vassarstats.net/
clin1.html). A p-value of < 0.05 was considered
statistically significant in all analyses.
Results

Statistics

The distribution of scores for all tumors is
reflected in Table 1. The majority of the leiomyosarcomas were strongly and diffusely positive for STMN1 expression (Figures 1 and 2),
whereas most leiomyomata were weakly positive or negative for STMN1 expression (Figures
3 and 4). At a ≥ 1+ threshold for positivity, all
spindle cell leiomyosarcomas were positive
(32/32 positive; 100%) as compared with conventional leiomyomata (11/30; 37%) (P <
0.0001). The average score for leiomyosarcomas was 8.7 (± 1.43) whereas the conventional
leiomyomata average score was 1.6 (± 1.07) (P
< 0.0001). This difference in scores was reflected in the patterns of expression: leiomyosarcomas were predominantly strongly and diffusely
positive whereas leiomyomata were predominantly weakly, albeit diffusely positive when
expression was present (Figure 4). The rate of
STMN1 positivity in LMS (32/32; 100%) was
significantly higher than for all other uterine SM
timors when the latter is considered as a group
(16/52; 30.8%) (P < 0.0001). All non-smooth
muscle tumors were positive.

Subgroups were compared regarding their
STMN1 staining using the Student t-test (comparing mean STMN1 score for each group) or
Fisher Exact test (comparing STMN1 rates of
positivity in each group). Odds Ratio, Sensitivity,

For each threshold for positivity, the sensitivity,
specificity, positive predictive value, and negative predictive value of the STMN1 as a biomarker for predicting a leiomyosarcoma diagnosis among the uterine smooth muscle tumors

Cases were scored using a system that incorporated staining intensity (on a 0-3+) scale and
staining extent (0-4+ scale). These values were
then multiplied in each case, giving potential
scores that ranged from 0-12+. All cases were
scored by 2 authors (MMA and OF).
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Figure 4. Leiomyoma with foci of no STMN1 expression (left image) and weak STMN1 expression (right image).

Table 2. Test parameters calculated for each threshold for positivity for smooth muscle tumors and all
tumors included in this study
Parameter
Smooth Muscle Tumors
Odds Ratio
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
All Tumors
Odds Ratio
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value

≥ 1+ (95% CI)

≥ 6+ (95% CI)

144 (8-2493, P = 0.0006)
100 (87-100)
69 (55-81)
67 (51-79)
100 (87-100)

17 (6-51, P < 0.0001)
78 (59-90)
83 (69-91)
73 (55-86)
86 (73-94)

33 (9-114, P < 0.0001)
78 (60-90)
90 (77-96)
83 (65-97)
87 (74-94)

80 (4-1370, P = 0.0024)
100 (87-100)
55.4 (43-68)
52.5 (39-65)
100 (87-100)

8.6 (3-23, P < 0.0001)
78.1 (60-90)
70.8 (58-81)
56.8 (41-71)
86.8 (74-94)

11 (4-30, P < 0.0001)
78.1 (60-90)
75.4 (63-85)
61 (45-75)
87.5 (75-94)

was calculated. We repeated the calculations
to determine the same parameters for STMN1
as a biomarker for predicting a leiomyosarcoma diagnosis in all uterine tumor cases that
were included in this study. Table 2 displays
each test parameter for each threshold for positivity for the smooth muscle tumors as well as
all tumors.
Using a threshold for positivity of ≥ 1+, the sensitivity of the STMN1 expression for leiomyosarcomas was 100% (95% confidence interval [CI]
= 87-100%). However, the specificity was found
to be only 55% (CI = 43-68%). The negative and
positive predictive values for leiomyosarcomas
were 100% (CI = 87-100%) and 52% (CI =
2798

Threshold for positivity
≥ 4+ (95% CI)

39-65%) respectively. The odds ratio (OR) for
any STMN1 expression in predicting a spindle
cell leiomyosarcoma diagnosis from this dataset was highly significant (OR = 144, CI = 8-2493,
P = 0.0006, at the ≥ 1+ threshold), see Table 2.
Discussion
The histologic classification of uterine smooth
muscle tumors regarding their malignant potential may potentially be problematic [12], and a
wide variety of immunohistochemical markers
have been assessed as potential diagnostic
adjuncts in this classification. Included in this
group are p21, p27, p53, p16, IMP3, pan-Akt,
Ki-67, progesterone receptor, and fascin [10,
Int J Clin Exp Pathol 2015;8(3):2795-2801
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16-26, 45]. These markers often have a specific drawback that limits their utility. For example, IMP3 is highly specific for leiomyosarcomas
but is only moderately sensitive (52% of the
leiomyosarcomas were positive, 4.2% of the
leiomyomata variants-cellular or symplasticwere positive, all conventional leiomyomata
were negative) [16]. Cell cycle regulatory protein expression (such as p16, p21, p27, and
p53) is often distinctly heterogeneous in
smooth muscle tumors and each cannot be
depended upon as a sole discriminator between
benign and malignant smooth muscle proliferations [10]. Composite profiles tend to be more
useful. For example, Lee et al reported that diffuse expression of p16 and p53 and/or a high
Ki-67 proliferation index, yielded a sensitivity of
92% and a specificity of 98% for separating
leiomyosarcomas from leiomyomata [20].
Fascin and Pan-AKT also show some potential
diagnostic utility, in that most leiomyosarcomas have been found to be positive and most
leiomyomata negative, but data are limited and
these markers have not been evaluated in multiple laboratories [17, 18].
The PI3K-AKT-mTOR pathway appears to be
centrally associated with smooth muscle proliferation and neoplasia in the uterus. In animal
models, mTOR has been shown to mediate hormone-initiated myometrial hyperplasia in pregnancy [42], and both mTOR and phosphatidylinositol-3 kinase have been reported to be
requirements for estrogen-induced proliferation in cell lines derived from uterine leiomyoma and normal myometrium [43]. Mice carrying
homologous deletions in an endogenous negative regulator of the P13K-Akt-mTOR pathway
developed a variety of benign smooth muscle
proliferations as well as rapid onset abdominal
leiomyosarcomas [27]. Although none of the
resultant malignancies were uterine, this study
was noteworthy because constitutive activation of the P13K-Akt-mTOR pathway was only
found in the leiomyosarcomas, and not the
benign proliferations, suggesting that PI3KAKT-mTOR pathway activation was a necessary
but insufficient event to develop smooth muscle malignancy [27]. The entire PI3K-AKT-mTOR
pathway is clearly upregulated in human
smooth muscle tumors as assessed by gene
expression profiling [44], and constitutive activation of the mTORC2-phospholipase D1 pathway has been demonstrated in uterine leiomyo-
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sarcoma (phospholipase D may be an activator
of mTOR signaling) [31]. Since STMN1 expression has also been identified as a significant
marker of activation of the PI3K-AKT-mTOR
pathway [36-40], we explored how well STMN1
expression correlated with histologic classifications of uterine smooth muscle tumors into
benign and malignant groupings. The ultimate
goal of this study was to explore the diagnostic
utility of this marker by establishing its baseline
performance in non-problematic cases.
We report that STMN1 is a highly sensitive
marker for leiomyosarcoma but is suboptimally
specific for diagnostic purposes. It is not a specific marker of malignancy within the smooth
muscle group since 37% of leiomyomata showed some STMN1 expression. It is also not a
specific marker of smooth muscle neoplasia
since non-smooth muscle sarcomas are frequently positive. The 100% negative predictive
value for leiomyosarcoma may offer some diagnostic utility in a small sample, in that the
absence of STMN1 immunoreactivity in a putative leiomyosarcoma is a strong argument
against the diagnosis. However, this marker
should be combined with other markers if
applied even for this purpose. Irrespective of
whether STMN1 can be applied for diagnostic
purposes, the patterns of expression may provide valuable insights into the elusive pathogenesis of leiomyosarcomas. For example, 5 of
5 atypical leiomyomas in our dataset were
STMN1 negative, indicating that STMN1 expression is not a surrogate indicator for cytologic
atypia and suggesting a lack of PI3K-AKT-mTOR
pathway activation in this morphologically distinct but biologically benign variant; in contrast,
2 of 2 mitotically active leiomyomata were positive. Since PI3K-AKT-mTOR play such a central
role in leiomyosarcomagenesis, STMN1 expression may provide insights into the primary drivers of this process, and/or their morphologic
correlates.
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